C21 Investments Inc.

CWLXF ·Healthcare, Drug Manufacturers - General
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $32.6M $30.1M $28.3M $28.9M $33.0M $33.5M $37.7M $2.6M
Cost of Revenue $19.0M $17.6M $17.1M $15.5M $14.2M $15.4M
Gross Profit $13.6M $12.6M $11.1M $13.4M $18.8M $18.0M
Gross Margin 41.7% 41.7% 39.4% 46.4% 57.0% 53.9%
Operating Expenses
Research & Development
SG&A Expense $11.3M $11.3M $9.7M $9.4M $9.1M $8.8M
Operating Income $2.3M $1.3M $1.5M $4.0M $9.8M $9.2M $-1.2M $-12.0M
Operating Margin 7.0% 4.3% 5.2% 13.7% 29.6% 27.6% -3.1% -465.2%
Interest Expense $187.2K $293.7K $35.2K $456.7K $1.1M $3.9M $3.9M $392.0K
Pretax Income $1.4M $394.9K $258.7K $4.2M $17.1M $-1.6M $-28.8M $-23.6M
Income Tax Expense $4.6M $4.2M $3.5M $2.8M $4.9M $3.0M $3.7M $0
Net Income $-3.2M $-4.0M $-3.3M $293.2K $10.0M $-7.8M $-32.6M $-23.6M
Net Margin -9.9% -13.2% -11.7% 1.0% 30.2% -23.4% -86.3% -912.8%
EPS (Basic) $-0.03 $-0.03 $-0.03 $0.00 $0.08 $-0.07
EPS (Diluted) $-0.03 $-0.03 $-0.03 $0.00 $0.08 $-0.07 $-0.43
Shares Outstanding (Basic) 117.9M 119.8M 120.0M 120.0M 118.3M 104.8M 89.4M 58.5M
Shares Outstanding (Diluted) 118.5M 120.6M 122.9M 122.9M 121.1M 104.8M 89.4M 58.5M
Dividends Per Share